The Clash of the Hep C Drugs Can Begin

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Years in the making, the hepatitis C battle can finally move from a battle of clinical-trial-laden press releases to a battle in the marketplace. Vertex Pharmaceuticals (Nasdaq: VRTX  ) announced today that the Food and Drug Administration approved Incivek. The thumbs-up comes on the heels of Merck's (NYSE: MRK  ) approval of Victrelis a little over a week ago.

The early winner will be the company that gets in front of doctors and makes it easy for patients to get reimbursement through their insurance. Merck has more experience in both areas than Vertex does, but Incivek means a lot more to the small biotech than Victrelis means to Merck. What it lacks in experience, Vertex may be able to make up for by throwing additional people at the problem. In Europe, once Incivek is approved there, the battle will be of equal-sized foes since Vertex licensed the EU rights to the drug to Johnson & Johnson (NYSE: JNJ  ) .

The midterm battle will still be over data. And Incivek still has the upper hand here. It cured as much as 79% of patients new to treatment, compared to Victrelis' 66%. The trials aren't completely comparable since the placebo group in the Incivek trial fared better than the comparable group in the Victrelis trial, but doctors have been known to overlook that important fact. Both labels include information about response-guided therapy, which allows doctors to stop pegylated-interferon and ribavirin taken with them if the patient shows an early response. Incivek's data support stopping the drugs, which have nasty side effects, after 24 weeks, while patients taking Victrelis will have to stay on the drugs for 28 weeks if the doctor is following the label.

Who will win the long term? There won't be one -- at least not as single agents: Victrelis vs. Incivek. The drugs are the first of the next-generation hepatitis C treatments, but there are plenty of drugs from Gilead Sciences (Nasdaq: GILD  ) , Bristol-Myers Squibb (NYSE: BMY  ) , Pharmasset (Nasdaq: VRUS  ) , and others coming up behind. They'll be combined with Victrelis and Incivek, first to remove pegylated-interferon and then to shoot for increased cure rates.

Investors need to keep one eye on sales data and the other on upcoming competitors and whether Merck and Vertex are forming partnerships with them.

Keep track of Merck and Vertex as they do battle in the hepatitis C market. Click here to add them to My Watchlist, which will help you keep track of all our Foolish analysis on the companies.

Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson, Gilead Sciences, and Vertex Pharmaceuticals and have recommended creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1498369, ~/Articles/ArticleHandler.aspx, 10/22/2016 5:47:59 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 20 hours ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
MRK $61.20 Down -0.72 -1.16%
Merck and Co. CAPS Rating: ****
VRTX $80.76 Down -2.16 -2.60%
Vertex Pharmaceuti… CAPS Rating: ****
BMY $50.02 Down -0.34 -0.68%
Bristol-Myers Squi… CAPS Rating: ****
GILD $74.29 Down -0.02 -0.03%
Gilead Sciences CAPS Rating: *****
JNJ $113.44 Down -1.43 -1.24%
Johnson and Johnso… CAPS Rating: ****
VRUS.DL $0.00 Down +0.00 +0.00%
Pharmasset, Inc. CAPS Rating: *